Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics (NASDAQ: AXSM), a biopharmaceutical company focused on CNS disorders, has announced its participation in six major investor conferences during September 2025. The company will engage in fireside chats at the Wells Fargo Healthcare Conference (Sept 3), Cantor Global Healthcare Conference (Sept 4), Morgan Stanley Global Healthcare Conference (Sept 8), Baird Global Healthcare Conference (Sept 10), and TD Cowen Novel Mechanisms Summit (Sept 17), followed by investor meetings at the Deutsche Bank Virtual BioPharm Corporate Day (Sept 18).
Live webcasts will be available for four of the presentations and can be accessed through Axsome's website, with replays available for approximately 30 days after each event.
Axsome Therapeutics (NASDAQ: AXSM), azienda biofarmaceutica specializzata nei disturbi del sistema nervoso centrale, ha comunicato la sua partecipazione a sei importanti conferenze con investitori nel settembre 2025. La società terrà presentazioni "fireside chat" al Wells Fargo Healthcare Conference (3 set), al Cantor Global Healthcare Conference (4 set), al Morgan Stanley Global Healthcare Conference (8 set), al Baird Global Healthcare Conference (10 set) e al TD Cowen Novel Mechanisms Summit (17 set), per poi effettuare incontri con investitori al Deutsche Bank Virtual BioPharm Corporate Day (18 set).
Quattro delle presentazioni saranno trasmesse in diretta via webcast e potranno essere seguite dal sito web di Axsome; le registrazioni saranno disponibili in replay per circa 30 giorni dopo ogni evento.
Axsome Therapeutics (NASDAQ: AXSM), una empresa biofarmacéutica centrada en trastornos del sistema nervioso central, ha anunciado su participación en seis importantes conferencias para inversores durante septiembre de 2025. La compañía realizará charlas informales (fireside chats) en el Wells Fargo Healthcare Conference (3 sept), el Cantor Global Healthcare Conference (4 sept), el Morgan Stanley Global Healthcare Conference (8 sept), el Baird Global Healthcare Conference (10 sept) y el TD Cowen Novel Mechanisms Summit (17 sept), y a continuación mantendrá reuniones con inversores en el Deutsche Bank Virtual BioPharm Corporate Day (18 sept).
Cuatro de las presentaciones se emitirán en directo por webcast y se podrán ver a través del sitio web de Axsome; las repeticiones estarán disponibles durante aproximadamente 30 días después de cada evento.
Axsome Therapeutics (NASDAQ: AXSM)는 중추신경계(CNS) 질환에 주력하는 바이오제약사로, 2025년 9월에 열리는 6개의 주요 투자자 콘퍼런스에 참가한다고 발표했습니다. 회사는 Wells Fargo Healthcare Conference(9월 3일), Cantor Global Healthcare Conference(9월 4일), Morgan Stanley Global Healthcare Conference(9월 8일), Baird Global Healthcare Conference(9월 10일), TD Cowen Novel Mechanisms Summit(9월 17일)에서 파이어사이드 챗(fireside chats)을 진행한 뒤, Deutsche Bank Virtual BioPharm Corporate Day(9월 18일)에서 투자자 미팅을 가질 예정입니다.
발표 중 4건은 라이브 웹캐스트로 제공되며 Axsome 웹사이트를 통해 시청할 수 있고, 각 행사 이후 약 30일 동안 다시보기(replay)가 제공됩니다.
Axsome Therapeutics (NASDAQ: AXSM), une société biopharmaceutique spécialisée dans les troubles du système nerveux central, a annoncé sa participation à six grandes conférences investisseurs en septembre 2025. La société donnera des "fireside chats" lors du Wells Fargo Healthcare Conference (3 sept.), du Cantor Global Healthcare Conference (4 sept.), du Morgan Stanley Global Healthcare Conference (8 sept.), du Baird Global Healthcare Conference (10 sept.) et du TD Cowen Novel Mechanisms Summit (17 sept.), puis tiendra des réunions avec des investisseurs lors du Deutsche Bank Virtual BioPharm Corporate Day (18 sept.).
Quatre des présentations seront diffusées en direct via webcast et pourront être consultées sur le site d'Axsome ; les replays seront disponibles environ 30 jours après chaque événement.
Axsome Therapeutics (NASDAQ: AXSM), ein Biopharmaunternehmen mit Schwerpunkt auf Erkrankungen des zentralen Nervensystems, hat seine Teilnahme an sechs wichtigen Investorenkonferenzen im September 2025 angekündigt. Das Unternehmen wird Fireside-Chats beim Wells Fargo Healthcare Conference (3. Sept.), Cantor Global Healthcare Conference (4. Sept.), Morgan Stanley Global Healthcare Conference (8. Sept.), Baird Global Healthcare Conference (10. Sept.) und TD Cowen Novel Mechanisms Summit (17. Sept.) führen und anschließend Investorengespräche beim Deutsche Bank Virtual BioPharm Corporate Day (18. Sept.) abhalten.
Vier der Präsentationen werden live per Webcast übertragen und sind über die Axsome-Website abrufbar; Replays stehen jeweils etwa 30 Tage nach der Veranstaltung zur Verfügung.
- None.
- None.
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September:
- 2025 Wells Fargo Healthcare Conference
Fireside Chat: Wednesday, September 3, 2025, at 3:45 p.m. ET in Boston, MA
- Cantor Global Healthcare Conference 2025
Fireside Chat: Thursday, September 4, 2025, at 1:00 p.m. ET in New York, NY
- Morgan Stanley 23rd Annual Global Healthcare Conference
Fireside Chat: Monday, September 8, 2025, at 2:35 p.m. ET in New York, NY
- Baird 2025 Global Healthcare Conference
Fireside Chat: Wednesday, September 10, 2025, at 3:10 p.m. ET in New York, NY
- TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Virtual Summit
Fireside Chat: Wednesday, September 17, 2025, at 8:40 a.m. ET
- Deutsche Bank Virtual BioPharm Corporate Day
Investor Meetings: Thursday, September 18, 2025
Live webcasts of the presentations at the Wells Fargo, Cantor, Morgan Stanley, and TD Cowen conferences can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at axsome.com. Replays of the webcasts will be available for approximately 30 days following each event.
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investors:
Ashley Dong
Director, Investor Relations
(929) 687-1614
adong@axsome.com
Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
FAQ
When is Axsome Therapeutics (AXSM) presenting at the Wells Fargo Healthcare Conference 2025?
How can investors access Axsome Therapeutics' (AXSM) conference presentations in September 2025?
Which investor conferences is Axsome Therapeutics (AXSM) attending in September 2025?
What type of company is Axsome Therapeutics (AXSM)?
